Dr Joćo Costa and colleagues systematically reviewed infliximab benefit in reducing hospitalizations, and/or major surgery rates in patients with inflammatory bowel disease (IBD).
A literature search to 2012 was performed to identify all studies evaluating patients with IBD treated with infliximab and providing data on hospitalizations and/or major surgery rates.
The team reported that 3 reviewers independently performed studies' selection, quality assessment, and data extraction.
Analyses were carried according to study design, and IBD type.
|Observational studies favored infliximab for Crohn's disease|
|Inflammatory Bowel Disease|
The research team included 27 eligible studies.
The team found that infliximab reduced hospitalization risk, both in pooled randomized controlled trials, and results of observational studies, without differences between Crohn's disease and ulcerative colitis.
Infliximab reduced surgery risk in pooled randomized controlled trials results, both in Crohn's disease and ulcerative colitis.
Pooled estimate from observational studies favored infliximab for patients with Crohn's disease, but not for patients with ulcerative colitis.
Dr Costa's team concluded, "The best evidence available points toward a reduction of the risk of hospitalization and major surgery requirement in patients with IBD treated with infliximab."
"This impact is clinically and economically relevant because hospitalization and surgery are considered to be markers of disease severity, and significantly contribute to the total direct costs associated with IBD."